Cargando…
Advantages of Combined PET-CT in Mediastinal Staging in Patients with Non-small Cell Lung Carcinoma
INTRODUCTION: Precise mediastinal lymph node staging in patients with non-small cell lung carcinoma (NSCLC) provides important prognostic information and it is obligatory in treatment strategy planning. 18Fluoro-deoxy-glucose (18F-FDG) positron emission tomography - computerized tomography (PET-CT)...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AVICENA, d.o.o., Sarajevo
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4851521/ https://www.ncbi.nlm.nih.gov/pubmed/27147799 http://dx.doi.org/10.5455/aim.2016.24.99-102 |
_version_ | 1782429831202340864 |
---|---|
author | Beslic, Nermina Sadija, Amera Milardovic, Renata Ceric, Timur Ceric, Sejla Beganovic, Adnan Kristic, Spomenka Cavaljuga, Semra |
author_facet | Beslic, Nermina Sadija, Amera Milardovic, Renata Ceric, Timur Ceric, Sejla Beganovic, Adnan Kristic, Spomenka Cavaljuga, Semra |
author_sort | Beslic, Nermina |
collection | PubMed |
description | INTRODUCTION: Precise mediastinal lymph node staging in patients with non-small cell lung carcinoma (NSCLC) provides important prognostic information and it is obligatory in treatment strategy planning. 18Fluoro-deoxy-glucose (18F-FDG) positron emission tomography - computerized tomography (PET-CT) based on detection of metabolic activity showed superiority in preoperative staging of lung carcinoma. MATERIALS AND METHODS: Total number of 26 patients diagnosed with NSCLC were included in this retrospective, cross-sectional study. Status of mediastinal lymph nodes was assessed in all patients comparing contrast enhanced CT and 18F-FDG PET-CT findings. DISCUSSION: We found in our study that 50% of patients had different N stage on contrast enhanced CT comparing to 18F-FDG PET-CT findings. Among the total number of patients which had different nodal status on PET-CT comparing to CT alone, we found in our study that 54% of patients had change in further therapy protocol after PET-CT change of nodal stage. CONCLUSION: Combined PET-CT which offers advantages of both modalities is excellent method for nodal (N) staging, so it is recommended in initial staging in patients with NSCLC. PET-CT used preopratively for mediastinal nodal staging has significant impact on further therapy planning and also has an consequential impact on health system savings. |
format | Online Article Text |
id | pubmed-4851521 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | AVICENA, d.o.o., Sarajevo |
record_format | MEDLINE/PubMed |
spelling | pubmed-48515212016-05-04 Advantages of Combined PET-CT in Mediastinal Staging in Patients with Non-small Cell Lung Carcinoma Beslic, Nermina Sadija, Amera Milardovic, Renata Ceric, Timur Ceric, Sejla Beganovic, Adnan Kristic, Spomenka Cavaljuga, Semra Acta Inform Med Original Paper INTRODUCTION: Precise mediastinal lymph node staging in patients with non-small cell lung carcinoma (NSCLC) provides important prognostic information and it is obligatory in treatment strategy planning. 18Fluoro-deoxy-glucose (18F-FDG) positron emission tomography - computerized tomography (PET-CT) based on detection of metabolic activity showed superiority in preoperative staging of lung carcinoma. MATERIALS AND METHODS: Total number of 26 patients diagnosed with NSCLC were included in this retrospective, cross-sectional study. Status of mediastinal lymph nodes was assessed in all patients comparing contrast enhanced CT and 18F-FDG PET-CT findings. DISCUSSION: We found in our study that 50% of patients had different N stage on contrast enhanced CT comparing to 18F-FDG PET-CT findings. Among the total number of patients which had different nodal status on PET-CT comparing to CT alone, we found in our study that 54% of patients had change in further therapy protocol after PET-CT change of nodal stage. CONCLUSION: Combined PET-CT which offers advantages of both modalities is excellent method for nodal (N) staging, so it is recommended in initial staging in patients with NSCLC. PET-CT used preopratively for mediastinal nodal staging has significant impact on further therapy planning and also has an consequential impact on health system savings. AVICENA, d.o.o., Sarajevo 2016-04 2016-03-26 /pmc/articles/PMC4851521/ /pubmed/27147799 http://dx.doi.org/10.5455/aim.2016.24.99-102 Text en Copyright: © 2016 Nermina Beslic, Amera Sadija, Renata Milardovic, Timur Ceric, Sejla Ceric, Adnan Beganovic, Spomenka Kristic, Semra Cavaljuga http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Paper Beslic, Nermina Sadija, Amera Milardovic, Renata Ceric, Timur Ceric, Sejla Beganovic, Adnan Kristic, Spomenka Cavaljuga, Semra Advantages of Combined PET-CT in Mediastinal Staging in Patients with Non-small Cell Lung Carcinoma |
title | Advantages of Combined PET-CT in Mediastinal Staging in Patients with Non-small Cell Lung Carcinoma |
title_full | Advantages of Combined PET-CT in Mediastinal Staging in Patients with Non-small Cell Lung Carcinoma |
title_fullStr | Advantages of Combined PET-CT in Mediastinal Staging in Patients with Non-small Cell Lung Carcinoma |
title_full_unstemmed | Advantages of Combined PET-CT in Mediastinal Staging in Patients with Non-small Cell Lung Carcinoma |
title_short | Advantages of Combined PET-CT in Mediastinal Staging in Patients with Non-small Cell Lung Carcinoma |
title_sort | advantages of combined pet-ct in mediastinal staging in patients with non-small cell lung carcinoma |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4851521/ https://www.ncbi.nlm.nih.gov/pubmed/27147799 http://dx.doi.org/10.5455/aim.2016.24.99-102 |
work_keys_str_mv | AT beslicnermina advantagesofcombinedpetctinmediastinalstaginginpatientswithnonsmallcelllungcarcinoma AT sadijaamera advantagesofcombinedpetctinmediastinalstaginginpatientswithnonsmallcelllungcarcinoma AT milardovicrenata advantagesofcombinedpetctinmediastinalstaginginpatientswithnonsmallcelllungcarcinoma AT cerictimur advantagesofcombinedpetctinmediastinalstaginginpatientswithnonsmallcelllungcarcinoma AT cericsejla advantagesofcombinedpetctinmediastinalstaginginpatientswithnonsmallcelllungcarcinoma AT beganovicadnan advantagesofcombinedpetctinmediastinalstaginginpatientswithnonsmallcelllungcarcinoma AT kristicspomenka advantagesofcombinedpetctinmediastinalstaginginpatientswithnonsmallcelllungcarcinoma AT cavaljugasemra advantagesofcombinedpetctinmediastinalstaginginpatientswithnonsmallcelllungcarcinoma |